33 results on '"Schönland, Stefan"'
Search Results
2. Machine Learning Can Distinguish Hypertrophic Cardiomyopathy, Cardiac Light Chain and Transthyretin Amyloidosis Using Cardiac Magnetic Resonance Imaging Data and Standard Clinical Information
3. Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation
4. P-076 The impact of heterogeneous disease distribution on MRD detection in patients with relapsed multiple myeloma
5. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results from the Real-World, Retrospective EMN23 Study
6. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia
7. A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma
8. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
9. P-277: Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma
10. Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells
11. Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation
12. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
13. P-175: Outcomes of autologous-allogeneic vs autologous tandem approach followed by thalidomide maintenance for transplant-eligible patients with newly diagnosed multiple myeloma: a prospective phase II-study
14. OAB-038: Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival
15. OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis
16. OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study
17. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study
18. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability
19. Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT
20. CT features in amyloidosis of the respiratory system – Comprehensive analysis in a tertiary referral center cohort
21. DUAL expectations in light chain amyloidosis
22. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
23. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
24. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
25. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era
26. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
27. Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients
28. Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances
29. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate
30. Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis
31. Amyloidogenicity of Immunoglobulin Light Chains
32. Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
33. Hereditary Apolipoprotein AI-Associated Amyloidosis in Surgical Pathology Specimens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.